[Gastroesophageal reflux: current status of therapy].

Leber, Magen, Darm Pub Date : 1995-07-01
E Seifert
{"title":"[Gastroesophageal reflux: current status of therapy].","authors":"E Seifert","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The aim in treatment of reflux oesophagitis is to relieve symptoms as well as to prevent complications and recurrence of the disease. The obvious preventive measures as abstinence from alcohol and nicotine and to sleep in a raised bed are useful for the health of the patient in general, but application on a whole is not possible and their efficiency in therapy of reflux oesophagitis is questionable. As to pharmaceutical treatment, proton pump inhibitors are the first line therapy. Such treatment enables the raising of pH levels over 4 to enable efficient acid blocking. It works directly on the key enzyme without being influenced by other environmental factors. Proton pump inhibitors have few side effects and they are suitable for long term treatment. In comparison to other medications proton pump inhibitors have proved to be significantly better in reducing symptoms of reflux oesophagitis in a shorter time. They also reduce healing time of peptic lesions and have proved to be efficient in higher stages of reflux oesophagitis and even in cases resistant to H2-inhibitors. H2-inhibitors have lost their place in the treatment of reflux oesophagitis with the arrival of proton pump inhibitors, because they are less effective, have a comparable number of side effects and are not prophylactic against relapse. Only patients complaining of reflux symptoms without provable morphological changes in the oesophago-gastral region are suitable for treatment with antacida or H2-inhibitors. There is a strict indication for long term treatment in stages with severe morphological changes (stage III or IV according to Savary and Miller) and in prevention of symptomatical relapse.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":17969,"journal":{"name":"Leber, Magen, Darm","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1995-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leber, Magen, Darm","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The aim in treatment of reflux oesophagitis is to relieve symptoms as well as to prevent complications and recurrence of the disease. The obvious preventive measures as abstinence from alcohol and nicotine and to sleep in a raised bed are useful for the health of the patient in general, but application on a whole is not possible and their efficiency in therapy of reflux oesophagitis is questionable. As to pharmaceutical treatment, proton pump inhibitors are the first line therapy. Such treatment enables the raising of pH levels over 4 to enable efficient acid blocking. It works directly on the key enzyme without being influenced by other environmental factors. Proton pump inhibitors have few side effects and they are suitable for long term treatment. In comparison to other medications proton pump inhibitors have proved to be significantly better in reducing symptoms of reflux oesophagitis in a shorter time. They also reduce healing time of peptic lesions and have proved to be efficient in higher stages of reflux oesophagitis and even in cases resistant to H2-inhibitors. H2-inhibitors have lost their place in the treatment of reflux oesophagitis with the arrival of proton pump inhibitors, because they are less effective, have a comparable number of side effects and are not prophylactic against relapse. Only patients complaining of reflux symptoms without provable morphological changes in the oesophago-gastral region are suitable for treatment with antacida or H2-inhibitors. There is a strict indication for long term treatment in stages with severe morphological changes (stage III or IV according to Savary and Miller) and in prevention of symptomatical relapse.(ABSTRACT TRUNCATED AT 250 WORDS)

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[胃食管反流:治疗现状]。
治疗反流性食管炎的目的是减轻症状以及预防疾病的并发症和复发。明显的预防措施,如戒除酒精和尼古丁,在抬高的床上睡觉,一般来说对病人的健康是有用的,但整体应用是不可能的,它们在治疗反流性食管炎方面的效率是值得怀疑的。在药物治疗方面,质子泵抑制剂是一线治疗。这样的处理可以将pH值提高到4以上,从而实现有效的酸阻断。它直接作用于关键酶而不受其他环境因素的影响。质子泵抑制剂副作用小,适合长期治疗。与其他药物相比,质子泵抑制剂已被证明在更短的时间内减轻反流性食管炎的症状。它们还缩短了消化性病变的愈合时间,并已被证明对较高阶段的反流性食管炎有效,甚至对h2抑制剂耐药的病例也有效。随着质子泵抑制剂的出现,h2抑制剂在反流性食管炎的治疗中已经失去了地位,因为它们的效果较差,副作用较少,并且不能预防复发。只有抱怨有反流症状且食管-胃区无可证实的形态学改变的患者才适合用抗酸剂或h2抑制剂治疗。在出现严重形态改变的阶段(根据Savary和Miller的说法是III期或IV期)和预防症状复发时,有严格的长期治疗适应症。(摘要删节250字)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Diagnosis and therapy of portal hypertension]. [Diagnosis and therapy of Helicobacter pylori infection. Guidelines of the German Society of Digestive and Metabolic Diseases. Working Group of the German Society of Digestive and Metabolic Diseases]. [Positive effect of ursodeoxycholic acid on liver enzymes in autoimmune hepatitis with little activity--a pilot study]. [Aortoduodenal fistula as the cause of gastrointestinal hemorrhage]. [Pseudo-esophagitis in antacid abuse].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1